Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Strong Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Buy

Insider Trading

Buy

Wall Street Data Solutions Rating

Buy

A

Merck & Co., Inc. (MRK)

Pharmaceutical Preparations

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

2000 GALLOPING HILL ROAD
KENILWORTH, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/20/1949

Market Cap

287,865,697,650

Shares Outstanding

2,534,020,000

Weighted SO

2,534,023,084

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

ABBV --.--%

PFE --.--%

LLY --.--%

BMY --.--%

AMGN --.--%

GILD --.--%

JNJ --.--%

Beta

0.3890

Last Div

3.0800

Range

99.14-134.63

Chg

0.2550

Avg Vol

9641322

Mkt Cap

287865697650

Exch

NYSE

Country

US

Phone

908 740 4000

DCF Diff

-50.1135

DCF

162.9600

Div Yield

0.0268

P/S

4.6042

EV Multiple

14.9010

P/FV

6.6030

Div Yield %

2.6769

P/E

20.9503

PEG

2.8827

Payout

0.5564

Current Ratio

1.4660

Quick Ratio

1.2178

Cash Ratio

0.4354

DSO

72.4711

DIO

147.4911

Op Cycle

219.9622

DPO

80.2321

CCC

139.7301

Gross Margin

0.7440

Op Margin

0.2730

Pretax Margin

0.2439

Net Margin

0.2197

Eff Tax Rate

0.0982

ROA

0.1220

ROE

0.3375

ROCE

0.1971

NI/EBT

0.9007

EBT/EBIT

0.8935

EBIT/Rev

0.2730

Debt Ratio

0.3355

D/E

0.8671

LT Debt/Cap

0.4434

Total Debt/Cap

0.4644

Int Coverage

18.3516

CF/Debt

0.4417

Equity Multi

2.5843

Rec Turnover

5.0365

Pay Turnover

4.5493

Inv Turnover

2.4747

FA Turnover

2.6925

Asset Turnover

0.5551

OCF/Share

6.5864

FCF/Share

5.1882

Cash/Share

4.4972

OCF/Sales

0.2669

FCF/OCF

0.7877

CF Coverage

0.4417

ST Coverage

5.4347

CapEx Coverage

4.7107

Div&CapEx Cov

1.4920

P/BV

6.6030

P/B

6.6030

P/S

4.6042

P/E

20.9503

P/FCF

21.8959

P/OCF

17.2423

P/CF

17.2423

PEG

2.8827

P/S

4.6042

EV Multiple

14.9010

P/FV

6.6030

DPS

3.0400

Latest Headlines (EST)

The Motley Fool Jun 14, 12:02 These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025 The Motley Fool Apr 26, 18:32 2 Outstanding Dividend Stocks to Buy and Hold For 20 Years GlobeNewswire Inc. Apr 12, 15:11 MRK DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK GlobeNewswire Inc. Apr 12, 15:11 ????? ?????? ?????? ??? MRK ???? ???: ????, ?????? ??????? ?????????, ????? ?? ?????? Merck & Co., Inc. ?? ?????? ?? ???? ?-100 ??? ???? ?????? ????? ???? ????? ?????? ????? ?? 14 ?????? ?????? ??????? ??????? ??? – MRK GlobeNewswire Inc. Apr 10, 22:53 Alarum Technologies Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses. April 15, 2025 Deadline to file Lead Plaintiff Motion. GlobeNewswire Inc. Apr 10, 22:46 Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion GlobeNewswire Inc. Apr 09, 21:36 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages enCore Energy Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EU The Motley Fool Mar 25, 22:47 Why Pharma and Biotech Stocks Got Thrashed on Tuesday GlobeNewswire Inc. Mar 13, 22:59 ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK GlobeNewswire Inc. Mar 10, 22:23 ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK The Motley Fool Mar 08, 15:02 Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? The Motley Fool Mar 08, 14:54 5 Top Stocks to Buy for March GlobeNewswire Inc. Mar 05, 00:57 ROSEN, A LEADING NATIONAL FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK GlobeNewswire Inc. Mar 01, 18:14 ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK GlobeNewswire Inc. Feb 27, 00:00 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK GlobeNewswire Inc. Feb 24, 03:54 ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK GlobeNewswire Inc. Feb 22, 22:15 MERCK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MRK GlobeNewswire Inc. Feb 20, 01:45 North America Leads the Beta-Glucan Boom: Market Insights & Industry Innovations GlobeNewswire Inc. Feb 19, 01:09 Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK The Motley Fool Dec 20, 23:32 Why Viking Therapeutics Tumbled by More Than 10% This Week

Revenue Product Segmentation